Related Experiment Videos

Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine

Neuroscience Letters
|January 27, 1987
PubMed

Insights

1-Methyl-4-phenylpyridine (MPP+), a parkinsonism-inducing compound, inhibits type A monoamine oxidase (MAO-A) in human brain mitochondria. This inhibition is most potent in the brain, suggesting a role in parkinsonism etiology.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • 1-Methyl-4-phenylpyridine (MPP+) is an oxidative product of MPTP, linked to parkinsonism.
  • Monoamine oxidases (MAOs) are crucial enzymes in neurotransmitter metabolism.

Purpose of the Study:

  • To investigate the effect of MPP+ on monoamine oxidase A (MAO-A) activity.
  • To determine the sensitivity of MAO-A from various sources to MPP+ inhibition.

Main Methods:

  • Kinetic analysis of MAO-A inhibition by MPP+.
  • Preparation of mitochondria from various human and animal tissues.
  • Determination of inhibition constants (Ki) for MPP+ on MAO-A.

Main Results:

  • MPP+ inhibits MAO-A in a competitive manner with the substrate kynuramine.
  • Human brain synaptosomal MAO-A exhibited the highest sensitivity to MPP+ inhibition (Ki = 1.3 μM).
  • MAO-A in striatum and cortex showed similar sensitivity to MPP+.

Conclusions:

  • MPP+ potently inhibits human brain MAO-A.
  • The specific lipid composition of mitochondria may influence MPP+ inhibition of MAO-A.
  • MPP+-induced MAO-A inhibition could contribute to the pathogenesis of parkinsonism.

Related Concept Videos